Not recruiting
Registered drug
Study on the Effects of Atacicept in Adults with IgA Nephropathy
Registered drug
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Atacicept
- Sponsor:Vera Therapeutics Inc.
Back to SpainClinical trials in Santiago De Compostela – page 54
682 clinical trials in Santiago De Compostela, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in SpainEnsayosClinicos.es(opens in a new tab)Santiago De Compostela at a glance
682
clinical trials
- Research sites3
Type of trial
Recruitment status
Quick filters
682 trials in Santiago De Compostela
Open in trial search
Not recruiting
Hidradenitis
Not recruitingInvestigational
Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
- Sponsor:Incyte Corp.
Not recruiting
Hormone receptor positive HER2 negative breast cancer
Not recruitingRegistered drugNo placebo
Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer
Registered drugNo placebo
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AbemaciclibCapivasertib+3
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
- Sponsor:AstraZeneca AB
Not recruiting
Colitis ulcerative
Not recruitingInvestigational
Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis
Investigational
- Disease:Colitis ulcerative
- Substances:Obefazimod
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Obefazimod
- Sponsor:Abivax
Not recruiting
Hidradenitis
Not recruitingInvestigational
Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:Spesolimab
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Spesolimab
- Sponsor:Boehringer Ingelheim Espana S.A.
Not recruiting
Colitis ulcerative
Not recruitingInvestigational
Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis
Investigational
- Disease:Colitis ulcerative
- Substances:Obefazimod
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Obefazimod
- Sponsor:Abivax
Not recruiting
Cardiac amyloidosis
Not recruitingRegistered drugNo placebo
Study on Long-Term Safety of Eplontersen for Adults with Transthyretin-Mediated Amyloid Cardiomyopathy
Registered drugNo placebo
- Disease:Cardiac amyloidosis
- Substances:Ascorbic Acid BpEplontersen+8
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Ascorbic Acid Bp
- Sponsor:Ionis Pharmaceuticals Inc.
Not recruiting
Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure
Not recruitingRegistered drugNo placebo
Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure
Registered drugNo placebo
- Substances:RisankizumabUstekinumab
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Risankizumab
- Sponsor:AbbVie Deutschland GmbH & Co. KG
Not recruiting
Endometrial cancer+4
Not recruitingRegistered drugNo placebo
Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer
Registered drugNo placebo
- Disease:Endometrial cancerTransitional cell carcinoma+3
- Substances:Anhydrous CaffeineParacetamol Dc+3
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Anhydrous Caffeine
- Sponsor:Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
Not recruiting
Osteoarthritis
Not recruitingInvestigational
Study on the Effects of RHH646 for Patients with Knee Osteoarthritis
Investigational
- Disease:Osteoarthritis
- Substances:Rhh646
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Rhh646
- Sponsor:Novartis Pharma AG
Not recruiting
Breast cancer+2
Not recruitingRegistered drugNo placebo
Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation
Registered drugNo placebo
- Disease:Breast cancerBreast cancer metastatic+1
- Substances:AlpelisibFulvestrant+3
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Alpelisib
- Sponsor:F. Hoffmann-La Roche AG
Not recruiting
Cardiovascular disorder
Not recruitingRegistered drug
Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
Registered drug
- Disease:Cardiovascular disorder
- Substances:Acetylsalicylic AcidClopidogrel+1
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Acetylsalicylic Acid
- Sponsor:Janssen Cilag International
Other cities in Spain
The busiest research cities in the country
- Madrid3 291 trials · 24 research sites
- Barcelona3 144 trials · 23 research sites
- Valencia1 777 trials · 8 research sites
- Sevilla1 634 trials · 4 research sites
- Malaga1 050 trials · 4 research sites
- L'hospitalet De Llobregat978 trials · 4 research sites
- Badalona767 trials · 3 research sites
- Pamplona753 trials · 1 research site
Clinical research in Santiago De Compostela
What the registry says about research in the country
01 Respiratory Infections Research
Innovative studies focusing on respiratory viral infections, including trials for RSV, influenza, and COVID-19 vaccines. Research aims to enhance protection in vulnerable populations, particularly adults over 60.
- RSV and hMPV vaccine development
- Influenza vaccine efficacy studies
- COVID-19 vaccine co-administration research
Multiple trials evaluating both single and combination vaccine approaches for respiratory diseases.
02 Cardiovascular Studies
Research targeting cardiovascular health and prevention, with emphasis on innovative treatments for stroke and heart failure. Studies include both therapeutic interventions and preventive measures.
- Acute cerebral ischemic stroke treatment
- Heart failure prevention strategies
- Cardiovascular risk management
Focus on developing new therapeutic approaches for better patient outcomes.
03 Dermatological Research
Advanced clinical investigations in dermatological conditions, particularly focusing on moderate to severe cases of psoriasis and atopic dermatitis.
- Plaque psoriasis treatments
- Psoriatic arthritis therapies
- Atopic dermatitis interventions
Trials evaluating novel therapeutic agents for chronic skin conditions.